Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

NCT01437605 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Treatment Ineffective

Conditions

Melanoma

Interventions

DRUG: MAGE-A3 ASCI injections without Poly IC:LC
DRUG: MAGE-A3 ASCI injections with Poly IC:LC

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]